medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2016, Número 3

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2016; 32 (3)


Síndrome de Behcet

Alfonso VME

Idioma: Español
Referencias bibliográficas: 78
Paginas: 301-315
Archivo PDF: 159.57 Kb.


RESUMEN

El síndrome de Behcet, también conocido como enfermedad de Behcet es un proceso autoinflamatorio crónico de baja frecuencia y etiología desconocida. Es una vasculitis que afecta arterias y venas de todos los calibres, provoca una alteración de la función endotelial y se expresa clínicamente con lesiones orgánicas en varios niveles. Tiene una mayor incidencia en los países localizados en la antigua ruta de la seda (mediterraneo del este, oriente medio y este de Asia). En su fisiopatogenia intervienen factores genéticos, microbianos e inmunológicos. Los síntomas varían de persona a persona y de acuerdo a las regiones geográficas, pero los más comunes son las úlceras orales y genitales, inflamaciones oculares (uveítis, retinitis e iritis), lesiones de piel y artritis. En algunos casos pueden presentarse alteraciones del sistema nervioso central, del tracto digestivo y renal. Como guía para el diagnóstico se emplean los criterios del grupo internacional de estudio de la enfermedad de Behcet. El tratamiento incluye medicamentos de uso tópico y sistémico, entre estos los más empleados son los esteroides, los inhibidores del factor de necrosis tumoral y los inmunosupresores.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. American Behcets disease association. Medical Summary of Behçet's Disease. Actualizado en 2014 por Calamia K. (visitado: Septiembre 28, 2015) Disponible en: http://www.behcets.com/site/c.8oIJJRPsGcISF/b.9145655/k.993C/Medical_Summary. htm

  2. Behcet H. Uber rezidivierende aphthose durch ein virus verursachte Geshwure am Munde am Auge un danden Gen-italien. Dematologische Wochenschrift. 1937;36:1152-7.

  3. Yazici H, Yazici Y. Criteria for Behçet's disease with reflections on all disease criteria. J Autoimmun. 2014;48-49:104-7.

  4. Mehta P, Laffan M, Haskard DO. Thrombosis and Behçet's syndrome in nonendemic regions. Rheumatology (Oxford). 2010;49(11):2003-4.

  5. Yazici Y, Yazici H. Behçet's syndrome. Curr Rheumatol Rep.2010;12(6):429-35

  6. Yazici H, Ugurlu S, Seyahi E. Behçet Syndrome: Is it one condition? Clinical Reviews in Allergy and Immunology 2012;43:275-80.

  7. International Team for the Revision of the International. Criteria for Behcet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338-47.

  8. Faezi ST, Paragomi P, Shahram F, Shams H, Shams-Davatchi C, Ghodsi Z,et al. Clinical features of Behçet's disease in patients without oral aphthosis. Mod Rheumatol. 2014 Jul;24(4):637-9. doi: 10.3109/14397595.2013.844400.

  9. Yazici Y, Simsek I, Yazici H. Behçet's Syndrome. In: Hoffman GS, Weyand CM, Langford CA, Goronzy JJ (eds). Inflammatory Diseases of Blood Vessels, 2nd Edition. Oxford: Wiley-Blackwell; 2012.p.289-98.

  10. Azizlerli G, Kose AA, Sarica R, Gül A, Tutkun IT, Kulaç M, et al. Prevalence of Behcet's disease in Istanbul, Turkey. Int J Dermatol. 2003 Oct;42:803-6.

  11. O'Neill TW, Rigby AS, Silman AJ, Barnes C. Validation of the International Study Group criteria for Behçet's disease. Br J Rheumatol. 1994;33(2):115-7.

  12. Calamia KT,Wilson FC,Icen M,Crowson CS,Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis Rheum. 2009 May 15;61(5):600-4.

  13. Mazzoccoli G, Matarangolo A, Rubino R, Inglese M, De Cata A. Behçet syndrome: from pathogenesis to novel therapies. Clin Exp Med. 2016 Feb;16(1):1-12. doi: 10.1007/s10238-014-0328-z.

  14. Gül A, Inanç M, Ocal L, Aral O, Koniçe M. Familial aggregation of Behcet's disease in Turkey. Ann Rheum Dis.2000;59:622-625.

  15. Molinari N, Koné Paut I, Manna R, Demaille J, Daures JP, Touitou I. Identification of an autosomal recessive mode of inheritance in paediatric Behçet's families by segregation analysis. Am J Med Genet.2003;122A:115-118

  16. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum.2009;61:1287-96.

  17. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al . Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet.2010;42:698- 702.

  18. Mizuki N, Meguro A, Ota M. Genome-wide association studies identify IL23RIL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet.2010;42:703-6.

  19. Moore SB, O'Duffy JD. Lack of association between Behçet's disease and major histocompatibility complex II antigens in an ethnically diverse North American Caucasoid patient group. J Rheumatol.1986;13:771-3.

  20. Masatlioglu S, Seyahi E, Tahir Turanli E, Fresko I, Gogus F, Senates E, et al. A twin study in Behçet's syndrome. Clin Exp Rheumatol.2010;28(Suppl 60):62-6.

  21. de Craen AJ, Posthuma D, Remarque EJ, van den Biggelaar AH, Westendorp RG, Boomsma DI. Heritability estimates of innate immunity: an extended twin study. Genes Immun.2005;6:167-70.

  22. Bird Stewart JA. Genetic analysis of families of patients with Behçet's syndrome: data incompatible with autosomal recessive inheritance. Ann Rheum Dis.1986;45:265-8.

  23. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore).2003;82:60-76

  24. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50:297-350.

  25. Baskan EB, Yilmaz E, Saricaoglu H, Alkan G, Ercan I, Mistik R, et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Behçet's disease. Clin Exp Dermatol. 2007;32:186-90.

  26. Hatemi G, Yazici Y, Yazici H. Behçet's syndrome. Rheum Dis Clin North Am. 2013;39(2):245-61.

  27. Direskeneli H, Hasan A, Shinnick T, Mizushima R, van der Zee R, Fortune F, et al. Recognition of B-cell epitopes of the 65 kDa HSP in Behçet's disease. Scand J Immunol. 1996;43:464-71.

  28. Suzuki Y, Hoshi K, Matsuda T, Mizushima Y. Increased peripheral blood gamma delta T cells and natural killer cells in Behçet's disease. J Rheumatol. 1992;19:588-92.

  29. Mumcu G, Inanc N, Aydin SZ, Ergun T, Direskeneli H. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behçet's disease. Clin Exp Rheumatol. 2009;27:S32-6.

  30. Apan TZ, Gursel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin associated gene-A in Behçet's disease. Clin Rheumatol. 2007;26:885-9.

  31. Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128-32.

  32. Musabak U, Pay S, Erdem H, Simsek I, Pekel A, Dinc A, Set al. Serum interleukin- 18 levels in patients with Behçet's disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int. 2006;26:545-50.

  33. Turan B, Pfister K, Diener PA, Hell M, Möller B, Boyvat A, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease. Scand J Rheumatol. 2008;37:135-41.

  34. Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement. Int J Dermatol. 2009;48:259-64.

  35. Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Arthritis Res Ther. 2012;14:R99.

  36. Shimizu J, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, et al. Excessive CD4? T cells co-expressing interleukin-17 and interferon c in patients with Behçet's disease. Clin Exp Immunol. 2012;168:68-74.

  37. Hamzaoui K. Th17 cells in Behçet's disease: a new immunoregulatory axis. Clin Exp Rheumatol. 2011;29:S71-6.

  38. Liang L, Wang H, Peng XY, Zhao M. The changes of Th lymphocyte subsets in patients with Behcet disease. Zhonghua Yan Ke Za Zhi. 2011;47:393-7.

  39. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis. 2013;72:1510-6.

  40. Gunesacar R, Erken E, Bozkurt B, Ozer HT, Dinkci S, Erken EG, et al. Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet's disease. Int J Immunogenet. 2007;34:45-9.

  41. Park KS, Baek JA, Do JE, Bang D, Lee ES. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet's disease. Tissue Antigens. 2009;74:222-7.

  42. Ben Dhifallah I, Chelbi H, Braham A, Hamzaoui K, Houman MH. CTLA-4 ?49A/G polymorphism is associated with Behçet's disease in a Tunisian population. Tissue Antigens. 2009;73:213-7.

  43. Pay S, Erdem H, Pekel A, Simsek I, Musabak U, Sengul A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis? Rheumatol Int. 2006;26:608-13.

  44. Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol. 2006;35:472-5.

  45. Suh CH, Park YB, Song J, Lee CH, Lee SK. Oligoclonal B lymphocyte expansion in the synovium of a patient with Behçet's disease. Arthritis Rheum.2001;44:1707-12.

  46. Direskeneli H, Keser G, D'Cruz D, Khamashta MA, Akoğlu T, Yazici H, et al. Antiendothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet's disease. Clin Rheumatol. 1995;14:55-61.

  47. Mahesh SP, Li Z, Buggage R, Mor F, Cohen IR, Chew EY, et al. Alpha tropomyosin as a self-antigen in patients with Behçet's disease. Clin Exp Immunol. 2005;140:368-75.

  48. Yavuz S, Elbir Y, Tulunay A, Eksioglu-Demiralp E, Direskeneli H. Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet's disease etiopathogenesis. Rheumatol Int.2008;28:401-6.

  49. Seoudi N, Bergmeier LA, Hagi-Pavli E, Bibby D, Curtis MA, Fortune F. The role of TLR2 and 4 in Behcet's disease pathogenesis. Innate Immun. 2014;20(4):412-22.

  50. Liu X, Wang C, Ye Z, Kijlstra A, Yang P. Higher expression of toll-like receptors 2, 3, 4, and 8 in ocular Behcet's disease. Investig Ophthalmol Vis Sci. 2013;54:6012-7.

  51. Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of toll-like receptors of monocytes from patients with Behcet's disease. Rheumatology (Oxford). 2008;47:840-8.

  52. Liang L, Tan X, Zhou Q, Zhu Y, Tian Y, Yu H, et al. IL-1b triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasomedependent pathways is involved in ocular Behçet's disease. Investig Ophthalmol Vis Sci. 2013;54:402-14.

  53. Al-Dalaan A, Al-Sedairy S, Al-Balaa S, al-Janadi M, Elramahi K, Bahabri S, et al. Enhanced interleukin 8 secretion in circulation of patients with Behçet's disease. J Rheumatol. 1995;22:904-7.

  54. Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann Rheum Dis. 1996;55:128-33.

  55. Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease: moderate correlation with antiendothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol. 1999;91:330-7.

  56. Hamzaoui K, Maıtre B, Hamzaoui A. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease. Clin Exp Rheumatol. 2009;27:S52-7.

  57. Espinosa G, Font J, Tassies D, Vidaller A,Vidaller A,Deulofeu R, López-Soto A,et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37-43.

  58. Buldanlioglu S, Turkmen S, Ayabakan HB,Yenice N,Vardar M, Dogan S, et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease. Br J Dermatol. 2005;153:526-30.

  59. Duygulu F, Evereklioglu C, Calis M, Borlu M, Cekmen M, Ascioglu O. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet's disease: a pilot study. Clin Rheumatol. 2005;24:324-30.

  60. Cekmen M, Evereklioglu C, Er H, Inalöz HS, Doganay S, Türköz Y, et al. Vascular endotelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome. Int J Dermatol. 2003;42:870-5.

  61. Hamzaoui K, Ayed K, Hamza M, Hamzaoui A. VEGF and mRNA VEGF expression in CSF from Behçet's disease with neurological involvement. J Neuroimmunol. 2009;213:148-53.

  62. Akar S, Ozcan MA, Ateş H, Gürler O, Alacacioglu I, Ozsan GH, et al. Circulated activated platelets and increased platelet reactivity in patients with Behçet's disease. Clin Appl Thromb Hemost. 2006;12:451-7.

  63. Yurdakul S, Hekim N, Soysal T, Fresko I , Bavunoglu I, Ozbakir F, et al. Fibrinolytic activity and d-dimer levels in Behçet's syndrome. Clin Exp Rheumatol. 2005;23:S53-8.

  64. Mat C, Goksugur N, Engin B,Yurdakul S, Yazici H. The frequency of scarring after genital ulcers in Behcet's syndrome:a prospective study. Int J Dermatol. 2006;45:554-6.

  65. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol.2004;138:373-380

  66. Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Characteristics of vascular involvement in Behçet's disease in Japan: a retrospective cohort study. Clin Exp Rheumatol.2011;29(Suppl 67):47-53.

  67. Akman-Demir G, Serdaroglu P, Tasci B; The Neuro-Behcet Study Group. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. Brain. 1999;122:2171-82.

  68. Saip S, Siva A, Altıntas A, Kiyat A, Seyahi E, Hamuryudan V, et al. Headache in Behcet's syndrome. Headache. 2005; 45:911-19.

  69. Korman U, Cantasdemir M, Kurugoglu S, Mihmanli I, Soylu N, Hamuryudan V, Yet al. Enteroclysis findings of intestinal Behcet disease: a comparative study with Crohn disease. Abdom Imaging. 2003; 28:308-12.

  70. Chang HK , Kim JW. The clinical features of Behçet's disease in Yongdong district: analysis of a cohort followed from 1997 to 2001. J Korean Med Sci.2002;17:784-9.

  71. Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan V, Yazici H. Gastrointestinal involvement in Behçet's syndrome: a controlled study. Ann Rheum Dis.1996;55:208- 10.

  72. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD) . The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47.

  73. Sabbadini MG, Franchini S. Behçet's Disease. Differential Diagnosis. En: Emmi L Ed. Behçet's Syndrome-From Pathogenesis to treatment. Milan: Springer-Verlog; 2014. p-177-188. DOI 10.1007/978-88-470-5477-6_3.

  74. Talarico R, d'Ascanio A, Neri R, Baldini C, Mosca M, Bombardieri S. Prognosis and Disease Activity. En: Emmi L Ed. Behçet's Syndrome-From Pathogenesis to treatment. Milan: Springer-Verlog; 2014. p. 199-205. DOI 10.1007/978-88-470-5477-6_3.

  75. Cantini F, Di Scala G. Old and New Treatment for Behçet's Disease. En: Emmi L Ed. Behçet's Syndrome-From Pathogenesis to treatment. Milan: Springer-Verlog; 2014. p. 207-16. DOI 10.1007/978-88-470-5477-6_3.

  76. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis.2012;71:563-6.

  77. American Behcets disease association. Treatment. (Visitado ago 25, 2015) Disponible en: http://www.behcets.com/site/c.8oIJJRPsGcISF/b.9145379/k.FED2/Treatment.htm

  78. Yurdakul S, Mat C, Tüzün Y,Ozyazgan Y,Hamuryudan V, Uysal O, et al. A doubleblind trial of colchicine in Behçet's syndrome. Arthritis Rheum.2001;44:2686-92.




2020     |     www.medigraphic.com